Alivus Life Sciences share price
You have to be logged in to add this to Watchlist.- ₹1,100.60(-2.89%)March 21, 2025 15:53:38 PM IST
- NSE
- BSE
- Vol : 47.71K (NSE + BSE)Last 20 day avg : 103.65 K
Alivus Life Sciences is trading -2.89% lower at Rs 1,100.60 as compared to its last closing price. Alivus Life Sciences has been trading in the price range of 1,136.25 & 1,094.00. Alivus Life Sciences has given 11.91% in this year & 7.48% in the last 5 days. Alivus Life Sciences has TTM P/E ratio 27.31 as compared to the sector P/E of 29.04.There are 4 analysts who have initiated coverage on Alivus Life Sciences. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 136.96 Crores in its last quarter.Listed peers of Alivus Life Sciences include Jubilant Pharmova (0.43%), Sanofi India (2.94%), Alivus Life Sciences (-2.89%).The Mutual Fund holding in Alivus Life Sciences was at 3.23% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Alivus Life Sciences was at 6.74% in 31 Dec 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 23, 2025, 11:47 AM UTC
- Dividend YieldHigher than industry2.04Annual dividends as a percentage of the stock price.
- P/B5.78The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values30.63Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.27Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 12.05% from Rs 641.84 crore to Rs 572.80 crore, year-on-year
- The company has grown its December quarter profit by 15.32% from Rs 118.77 crore to Rs 136.96 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,034.32
- R2
- 1,183.08
- R3
- 1,266.67
- S1
- 801.97
- S2
- 718.38
- S3
- 569.62
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova | Moderately Bearish | 902.85 | 0.43 | 14,380.70 | 96.18 | 2.63 | 0.55 | 61.92 |
| Sanofi India | Moderately Bullish | 5,875.05 | 2.94 | 13,530.61 | 39.67 | 15.72 | 1.99 | 1.63 |
| Alivus Life Sciences | Bullish | 1,100.60 | -2.89 | 13,485.97 | 28.64 | 5.78 | 2.04 | 0.63 |
| Granules India | Neutral | 507.45 | 1.42 | 12,305.34 | 30.21 | 3.81 | 0.30 | 4.72 |
| Marksans Pharma | Neutral | 216.84 | -0.24 | 9,829.11 | 30.15 | 4.76 | 0.28 | 9.20 |
- Promoter(s) holds a high stake in the company at 75.00%
Promoter(s) have decreased the stake in the company in last 12 months- FIIs are invested in this company
- FIIs holding has decreased by 1.11 percentage points from previous quarter
- Mutual Funds holding has increased by 0.41 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-01-23 | Quarterly Results |
| 2024-10-24 | Quarterly Results |
| 2024-07-25 | Quarterly Results |
| 2024-04-25 | Audited Results |
| 2024-01-23 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE03Q201024
- BSE Code143322
- NSE CodeALIVUS
Alivus Life Sciences is trading at 1100.60 as on Fri Mar 21 2025 10:23:38. This is -2.89% lower as compared to its previous closing price of 1133.40.
The market capitalization of Alivus Life Sciences is 13485.97 Cr as on Fri Mar 21 2025 10:23:38.
The average broker rating on Alivus Life Sciences is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Alivus Life Sciences is 1335.10 whereas the 52 wk low is 719.75
Alivus Life Sciences can be analyzed on the following key metrics -
- TTM P/E: 27.31
- Sector P/E: 29.04
- Dividend Yield: 2.04%
- D/E ratio: -
Alivus Life Sciences reported a net profit of 470.89 Cr in 2024.
The Mutual Fund Shareholding was 3.23% at the end of 31 Dec 2024.